Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi winthrop industrie - kabasitaksel - eesnäärmevähk - antineoplastilised ained - jevtana koos prednisooni või prednisolooniga on näidustatud hormoon-refraktaarse metastaatilise eesnäärmevähiga dotsetakseeli sisaldava raviskeemiga ravitud patsientide.

Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - kartsinoom, mitteväikerakk-kopsu - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Eesti - eesti - Ravimiamet

teva b.v. - kabasitakseel - infusioonilahuse kontsentraat - 10mg 1ml 6ml 1tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - kabasitakseel - infusioonilahuse kontsentraat - 10mg 1ml 6ml 5tk; 10mg 1ml 4.5ml 1tk; 10mg 1ml 6ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastilised ained - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies.  follicular lymphoma (fl) that is refractory to at least two prior  systemic therapies.

Eesti - eesti - Ravimiamet

zentiva k.s. - kabasitakseel - infusioonilahuse kontsentraat ja lahusti - 60mg 1.5ml 1.5ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastilised ained - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Eesti - eesti - Ravimiamet

fresenius kabi polska sp. z o.o. - kabasitakseel - infusioonilahuse kontsentraat - 20mg 1ml 3ml 1tk

Eesti - eesti - Ravimiamet

teva b.v. - kabasitakseel - infusioonilahuse kontsentraat - 10mg 1ml 6ml 1tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - kabasitakseel - infusioonilahuse kontsentraat - 20mg 1ml 3ml 1tk